Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients

Breast Cancer Research and Treatment
Andy GöbelTilman D Rachner

Abstract

Endocrine therapies, including tamoxifen or aromatase inhibitors, are indispensable for the treatment of patients with estrogen receptor (ER)- and/or progesterone-positive breast cancer. Whereas tamoxifen displays partial ER agonistic effects in bone, aromatase inhibitors increase bone resorption and fracture risk. The Wnt inhibitors dickkopf-1 (DKK-1) and sclerostin negatively impact bone formation and are considered targets for the treatment of bone disorders. However, the effect of endocrine therapies on serum DKK-1 and sclerostin levels in patients with primary breast cancer remains elusive. Serum DKK-1 and sclerostin levels were measured at primary diagnosis as well as 3-5 days and 12 months after surgery in a cohort of 45 pre- and postmenopausal women with primary estrogen receptor-positive breast cancer treated with adjuvant tamoxifen or aromatase inhibitors. Mean baseline levels ±SD for DKK-1 and sclerostin were 29.7 ± 14.6 and 27.1 ± 16.2 pmol/l, respectively. A significant negative correlation of DKK-1 levels and age was observed (r = -0.32; p < 0.05), but not for sclerostin. Of note, DKK-1 levels were significantly lower in peri- and postmenopausal women compared to premenopausal patients (-47%; p < 0.05). In tamoxif...Continue Reading

References

Aug 3, 2002·Nature Reviews. Cancer·Gregory R Mundy
Mar 7, 2003·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Petri LehenkariH Kalervo Väänänen
May 5, 2005·Cytokine & Growth Factor Reviews·Rutger L van BezooijenClemens W G M Löwik
Jun 24, 2006·The Oncologist·Kadri Altundag, Nuhad K Ibrahim
Sep 19, 2007·British Journal of Cancer·N Voorzanger-RousselotP Garnero
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard EastellGlen Clack
Jun 1, 2010·Mayo Clinic Proceedings·Julia A FilesSandhya Pruthi
Aug 20, 2010·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Ulrike I MödderSundeep Khosla
Jun 23, 2012·Endocrine Reviews·Hua Zhu KeMichael S Ominsky
Feb 8, 2013·Nature Medicine·Roland Baron, Michaela Kneissel
Mar 15, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J FerlayF Bray
Feb 18, 2014·Breast Cancer Research : BCR·Tilman D RachnerLorenz C Hofbauer
Jul 28, 2015·Lancet·UNKNOWN Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Mar 28, 2016·Calcified Tissue International·Natasha M Appelman-Dijkstra, Socrates E Papapoulos

❮ Previous
Next ❯

Citations

Sep 22, 2018·Clinical & Experimental Metastasis·Mariz KasohaErich-Franz Solomayer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.